{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:08:20Z","timestamp":1773673700473,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2470,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,10,2]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Functional dyspepsia is a problem that is difficult to treat in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with functional dyspepsia (<jats:italic>n<\/jats:italic>=557) were divided a priori into two studies by <jats:italic>Helicobacter pylori<\/jats:italic> status, and enrolled in a 2\u2010week baseline evaluation period. Ninety\u2010nine patients with <jats:italic>Helicobacter pylori<\/jats:italic> and 173 patients without <jats:italic>Helicobacter pylori<\/jats:italic>, continuing to have at least moderate upper abdominal pain or discomfort, were randomly assigned to rebamipide 100\u2003mg, rebamipide 200\u2003mg or placebo, three times a day, in a double\u2010blind design for 8\u2003weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>There was significant improvement of individual symptom scores from baseline in all the treatment arms. No significant improvement of individual symptom scores was observed in either rebamipide group at the end of the studies compared to placebo, although the belching score was significantly reduced in the rebamipide 100\u2003mg and 200\u2003mg groups at week 2 (<jats:italic>P<\/jats:italic>=0.017 and <jats:italic>P<\/jats:italic>=0.012, respectively) in the <jats:italic>Helicobacter pylori<\/jats:italic>\u2010positive patients. The ratio of patients who requested usage of the study medication again was greater in the rebamipide 100\u2003mg (85%) and 200\u2003mg (96%, <jats:italic>P<\/jats:italic>=0.020) groups compared with the placebo group (72%) among <jats:italic>Helicobacter pylori<\/jats:italic>\u2010positive patients. There were no serious study medication related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Rebamipide was not superior to placebo in terms of individual symptoms at the end of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01074.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:10Z","timestamp":1047354190000},"page":"1603-1611","source":"Crossref","is-referenced-by-count":30,"title":["Double\u2010blind placebo\u2010controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without <i>Helicobacter pylori<\/i> infection"],"prefix":"10.1111","volume":"15","author":[{"given":"N. J.","family":"Talley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Riff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"Marcuard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90764-P"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537277"},{"key":"e_1_2_6_4_2","first-page":"1407","article-title":"Nonulcer dyspepsia: current approaches to diagnosis and management","volume":"47","author":"Talley NJ.","year":"1993","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_5_2","first-page":"145","article-title":"Functional dyspepsia: a classification with guidelines for diagnosis and management","volume":"4","author":"Talley NJ","year":"1991","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-865"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6521.665"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529109109537"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528809093840"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00410.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)70018-S"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90004-I"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199812000-00002"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529409092482"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/1997\/314839"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.49.441"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0928-4680(94)90006-X"},{"key":"e_1_2_6_18_2","first-page":"359","article-title":"Influence of rebamipide on indometacin\u2010induced gastric hemorrhage in rats under restraint stress","volume":"49","author":"Yamasaki K","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_19_2","first-page":"5S","article-title":"Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing","volume":"43","author":"Arakawa T","year":"1998","journal-title":"Dig Dis Sci"},{"key":"e_1_2_6_20_2","first-page":"1462","article-title":"Effect of rebamipide on mucus secretion by endogenous prostaglandin\u2010independent mechanism in rat gastric mucosa","volume":"42","author":"Ishihara K","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1998.tb00984.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90649-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01308601"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90065-C"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.10.1375"},{"key":"e_1_2_6_26_2","first-page":"167S","article-title":"Nonopsonic activation of neutrophils by Helicobacter pylori is inhibited by rebamipide","volume":"43","author":"Danielsson D","year":"1998","journal-title":"Dig Dis Sci"},{"key":"e_1_2_6_27_2","first-page":"363","article-title":"Free radical scavenging activity of the novel anti\u2010ulcer agent rebamipide studied by electron spin resonance","volume":"43","author":"Yoshikawa T","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(94)00110-6"},{"key":"e_1_2_6_29_2","first-page":"174S","article-title":"Molecular analysis of suppression of interleukin\u20108 production by rebamipide in Helicobacter pylori\u2010stimulated gastric cancer cell lines","volume":"43","author":"Aihara M","year":"1998","journal-title":"Dig Dis Sci"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii37"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01535722"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392602"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90007-8"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910073411502"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.1.55"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912073212302"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018861818023"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018829032175"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02065543"},{"key":"e_1_2_6_40_2","first-page":"340","article-title":"Preventive effect of rebamipide on gastric lesions induced by ischemia\u2010reperfusion in the rat","volume":"275","author":"Kim CD","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_41_2","first-page":"99S","article-title":"Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status","volume":"43","author":"Higuchi K","year":"1998","journal-title":"Dig Dis Sci"},{"key":"e_1_2_6_42_2","first-page":"G401","article-title":"Nitric oxide: mediator of nonadrenergic noncholinergic responses of opossum esophageal muscle","volume":"261","author":"Murray J","year":"1991","journal-title":"Am J Physiol"},{"key":"e_1_2_6_43_2","first-page":"118S","article-title":"IFN\u2010gamma\u2010induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells","volume":"43","author":"Nagano C","year":"1998","journal-title":"Dig Dis Sci"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01074.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01074.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01074.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:04:48Z","timestamp":1697537088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01074.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,2]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,2]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01074.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01074.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,2]]}}}